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Abstract
Background O-Linked β-N-acetylglucosamine (O-GlcNAc)
is an enzyme-catalyzed posttranslational modification of
serine or threonine side chains of nuclear and cytoplasmic
proteins. O-GlcNAc is present in all metazoans and in
viruses that infect eukaryotic cells. GlcNAcylation is
dynamic and has a high cycling rate on many proteins in
response to cellular metabolism and various environmental
stimuli. The rapid cycling of O-GlcNAc modulates many
biological processes, including transcriptional regulation,
stress responses, cell cycle regulation, and protein synthesis
and turnover.
Rationale Despite the importance of O-GlcNAc, progress
during the past two decades in this field has been slow. One
of the major obstacles is the lack of simple and sensitive
tools for efficient O-GlcNAc detection and localization.
Recently developed O-GlcNAc derivatization and enrich-
ment approaches, together with new techniques in mass
spectrometric instrumentation and methods, have provided
breakthroughs in O-GlcNAc site localization and site-
specific quantitation. In this review, we will discuss how
the current techniques are expanding our knowledge about
O-GlcNAc proteomics/glycomics and functions.
Keywords Glycomics .O-GlcNAc . GlcNAcylation .
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Introduction
Protein GlcNAcylation is distinct from classical “mucin-type”
O-glycosylation. First, O-linked β-N-acetylglucosamine
(O-GlcNAc) is found only on nuclear and cytoplasmic
proteins, and not on secreted or cell surface glycoproteins.
Second, O-GlcNAc is a monosaccharide modification and is
generally not further elongated to complex structures. Similar
to phosphorylation, GlcNAcylation is ubiquitous and abun-
dant. Since its discovery more than 25 years ago [1, 2], about
600 proteins have been identified as O-GlcNAc-modified
[3], and this number is growing rapidly with recent advances
in O-GlcNAc detection. Cycling of O-GlcNAc is catalyzed
by two unique enzymes: N-acetylglucosaminyltransferase
(OGT) and N-acetyl-β-D-glucosaminidase (O-GlcNAcase).
OGT catalyzes the addition of O-GlcNAc using uridine 5′-
diphosphate-GlcNAc (UDP-GlcNAc) as the donor substrate.
UDP-GlcNAc is the major end product of hexosamine
biosynthetic pathways and exists within the cells at concen-
trations ranging from of hundreds of micromolars to
millimolars, which approaches the intracellular concentration
of ATP [4]. Unlike phosphorylation, for which there are
hundreds of site/protein-specific kinases [5], there is only
one highly conserved gene encoding the OGT catalytic
subunit in mammals and two encoding OGT in plants [6, 7].
Likewise, only a single highly conserved gene encoding
O-GlcNAcase, the enzyme that removes O-GlcNAc, exists
in mammals [8], and the plant O-GlcNAcase remains to be
identified. O-GlcNAcase is distinct from lysosomal hexosa-
minidases in both its subcellular localization and pH
optimum. Transient transfection, resulting in overexpression
of O-GlcNAcase, can lead to dramatic decreases in overall
O-GlcNAcylation within cells [3].
O-GlcNAc is relatively small and uncharged. Therefore,
its addition and its removal usually do not affect a protein’s
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mobility in gel electrophoresis, even on high-resolution, two-
dimensional gels. O-GlcNAc was first discovered in experi-
ments designed to enzymatically label terminal GlcNAc on
lymphocytic proteins with β1,4-galactosyltransferase (GalT)
and tritiated UDP-galactose (UDP-Gal) [1]. GalT labeling
after PNGase F (an enzyme that cleaves N-linked carbohy-
drates) treatment, followed by β-elimination and analyses of
the released disaccharide product, provides unambiguous
evidence that the target protein is O-GlcNAc modified.
This method remains the “gold” standard to detect O-
GlcNAcylated proteins using non-mass spectrometric
approaches. This original method also served as the basis
for the earliest O-GlcNAc site-mapping, which involved
time-consuming multiple-step procedures [9–15]. Briefly, a
[3H] Gal-labeled peptide mixture is first separated by
multiple rounds of reverse-phase high-performance liquid
chromatography (HPLC), pooling only the radiolabeled
fractions. Finally, O-GlcNAc site information is obtained
by monitoring the release of radioactivity by gas-phase
Edman automated sequencing or by manual Edman degra-
dation [13–15]. Robustness of this method is complicated by
multiple factors, such as performance of the HPLC purifica-
tion and the intrinsic limitation of Edman degradation.
Moreover, due to substantial sample loss during each HPLC
cycle, fairly large amounts of starting material are required
(nano- to submicromolar), which is usually not practical for
low-abundance regulatory proteins with substoichiometric
modification at any single site.
Proteomic Approaches for Identification
of GlcNAcylated Proteins
Besides [3H] Gal enzymatic labeling, other important tools
for O-GlcNAc studies include pan-specific O-GlcNAc
antibodies CTD 110.6 or RL2 [16, 17], which are able to
detect O-GlcNAc-modified proteins by Western blotting. A
straight-forward method to identify GlcNAcylated proteins
is to run identical samples over two separate gels. One gel
is used for Western blotting with O-GlcNAc antibodies.
The other is used for protein staining. Corresponding
protein bands/spots are then excised, protease digested,
and identified by either mass fingerprint (matrix-assisted
laser desorption ionization–time of flight, MALDI-TOF) or
liquid chromatography–mass spectrometry (LC-MS/MS).
This approach has been used in a number of studies to
identify novel O-GlcNAc proteins in various biological
tissues. The limitation of this approach lies in two aspects.
Currently available pan-specific O-GlcNAc antibodies have
relatively low binding affinity. Thus, in many cases, only
multiply modified, higher-molecular-weight, or highly
abundant proteins can be detected by the antibodies. In
addition, there are chances for nonspecific binding. Sec-
ondly, and most importantly, it is very common that an
apparent single-protein band may actually contain multiple
proteins. This is true even when high-resolution two-
dimensional gels have been employed. Thus, it is possible
that a low abundant, highly GlcNAcylated protein is
antibody-reactive, while in mass spectrometric analysis,
only protein(s) of higher abundance are actually identified.
In such cases, this approach will lead to erroneous results. A
variation to this approach is to first purify O-GlcNAcylated
proteins with immunoaffinity chromatography, and then
identify the bound proteins after elution [18]. Similarly, due
to nonspecific and indirect binding, all of such identifica-
tions can only be considered tentative until they are further
confirmed by other methods. A simple approach to confirm
GlcNAcylation is to immuoprecipitate the target protein,
followed by immunoblotting with O-GlcNAc antibodies.
Antibody specificity controls should also be performed to
rule out nonspecific binding in immunblotting, such as
pretreatment of a part of the sample with hexosaminidase
and/or by adding free GlcNAc in primary antibody solution
to compete specific antibody binding [13–15, 18].
Recently, in addition to the immunoaffinity approaches,
GlcNAcylated proteins can also be enriched and purified by
chemical tagging. Vocadlo et al. [19] fed cells during cell
culture with a peracetylated form of N-azidoacetylglucosamine,
which is converted into UDP-azido-GlcNAc (UDP-GlcNAz)
in vivo by the hexosamine salvage pathway. UDP-GlcNAz is a
structural analog of UDP-GlcNAc with the N-acyl side chain
modified into an azide group. In vitro OGT assays showed that
recombinant OGT could tolerate this unnatural substrate and
labeled proteins with GlcNAz. The azide moiety then allows
facile conjugation to a biotinylated phosphine probe via
Staudinger ligation, facilitating selective enrichment of O-
GlcNAc-modified proteins by avidin chromatography [19].
Nandi et al. [20] adopted this strategy in their glycomic
analysis for GlcNAcylated proteins, which they termed the
“tagging-via-substrate approach,” and they successfully iden-
tified 199 putative O-GlcNAc-modified proteins, both known
and novel. The advantage of this approach is that it provides
superior binding affinity and selectivity over immunoaffinity-
based methods for enrichment of O-GlcNAc proteins. The
high affinity between biotin and streptavidin allows stringent
washing and high selectivity, which allows hundreds of
proteins to be identified in one simple analysis. However, the
low efficiency of free GlcNAz conversion to UDP-GlcNAz
and the relatively poor efficiency of UDP-GlcNAz utilization
by endogenous OGT as a donor substrate, relative to the
natural substrate, limit the utility of the method. More
importantly, since OGT’s natural substrate, UDP-GlcNAc,
approaches nearly millimolar level in concentration within the
cells, most likely only a very small fraction of added UDP-
GlcNAz can be actually utilized by OGT. As a consequence,
only heavily GlcNAcylated proteins or highly abundant
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GlcNAcylated proteins are readily labeled and enriched by this
approach. Also, since the hexosamine biosynthesis pathway is
closely linked to glucose metabolism, feeding cells with large
amount of the GlcNAc analog, GlcNAz, may induce unknown
alterations on in vivo metabolism.
Proteomic/Glycomic Approaches to Map Site
of O-GlcNAc Modification
An unambiguous alternative to identifying O-GlcNAc
proteins is to directly map the modification sites. Mapping
O-GlcNAc sites is essential for functional studies, including
site-directed mutagenesis to investigate the role(s) of O-
GlcNAc in protein function. Until recently, only very
limited numbers of O-GlcNAc sites have been unambigu-
ously identified [21]. The lack of site information imposes a
major obstacle for studies of O-GlcNAcylation because it
makes it impossible to design site-specific O-GlcNAc
antibodies, which would provide valuable tools for under-
standing the regulatory roles of O-GlcNAc. Site-specific
phosphorylation antibodies have played a key role in the
elucidation of phosphorylation’s functions in signaling
cascades [22].
Mass Spectrometry: O-GlcNAc is Labile in the Gas
Phase
The difficulties of mapping O-GlcNAc lie in three major
aspects: its intrinsic lability in gas phase, relatively low
abundance, and severe ion suppression effect in the
presence of unmodified peptides. When peptides carrying
O-GlcNAc are fragmented by standard collisionally acti-
vated dissociation (CAD) with inert gas, most of the kinetic
energy is lost by the cleavage at the O-GlcNAc moiety,
which easily falls off and generates a major neutral loss
peak. This phenomenon is also well known for some
Ser/Thr phosphorylated peptides. However, in case of O-
GlcNAc, it is even worse because, unlike phosphopeptides,
which usually still have certain degrees of backbone
fragmentation, there is typically very little or no peptide
backbone fragmentation for all O-GlcNAc peptides exam-
ined to date under standard CAD conditions (Fig. 1).
Moreover, O-GlcNAc is also lost at the electrospray
ionization interface and at the ion optics, presumably due
to in-source fragmentation ([11]; data not shown). Of
course, further fragmentation of the neutral loss peak in
the ion trap (MS3) can achieve identification of the peptide.
However, unless there is only one Ser or Thr residue in the
peptide, unambiguous site-mapping is not possible because
all modification site information has been lost.
Studies by Haynes and Aebersold [23] employed
precursor ion scanning with low collision energy on a
triple quadrupole instrument to first detect peptides that
generated signature peaks corresponding to loss of the O-
GlcNAc moiety. They then used CAD at higher energy to
fragment and sequence the peptides that were initially O-
GlcNAc-modified. Using this method, they managed to
confine one O-GlcNAc site on bovine α-crystallin to a 16-
amino-acid carboxyl terminal peptide, which had five
serine residues as potential O-GlcNAc sites. Chalkley and
Burlingame [24] adopted a very similar strategy on a
quadrupole time-of-flight instrument. These investigators
used lowered collision energy to fragment preselected
precursor ions that produced diagnostic GlcNAc oxonium
ions under standard CAD condition, thus improving the
possibility of generating GlcNAc-carrying fragments. Using
this method, Chalkely et al. were able to locate several O-
GlcNAc sites on synthetic peptides and on serum response
factor. However, all these studies had to use rather large
amounts of samples (synthetic O-GlcNAc peptides or
Fig. 1 O-GlcNAc site informa-
tion is lost before peptide back-
bone fragmentation. CAD MS/
MS spectrum of GlcNAcylated
peptide (YSPTgSPSK,
[M+GlcNAc+2H]2+ 535.2)
showing a major peak [M+H]+
866.3 corresponding to loss of
GlcNAc
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overexpressed and purified recombinant O-GlcNAc pro-
teins), which is not practical for most endogenous complex
and substoichiometric biological samples.
Enrichment is Key for O-GlcNAc Site-mapping
Recent proteomic analyses have been able to identify
hundreds of phosphorylation sites in one experiment. This
is in part due to extensive fractionation and, more
importantly, the specific enrichment of phosphopeptides,
such as by strong cation exchange [25], immobilized metal
ion chromatography [26], titanium dioxide [27], etc.
Without enrichment, it is difficult to detect phosphopeptides
because they are usually in low abundance and suffer from
low ionization efficiency. We observe similar (or even worse)
ion suppression effects for O-GlcNAc peptides. O-GlcNAc
peptide ionization is suppressed 5- to 10-fold under the
presence of unmodified peptides in matrix-assisted laser
desorption ionization (Fig. 2A). GlcNAcylated peptides
usually coelute with the unmodified forms on reverse-phase
HPLC (Fig. 2B). Electrospray ionization of GlcNAcylated
peptides is suppressed in the presence of the unmodified
peptides (Fig. 3C). Thus, it is obvious that the detection of
O-GlcNAc peptides in substoichiometric biological sam-
ples, where the molar percentage of O-GlcNAc peptides is
usually even lower, is almost impossible without specific
enrichment.
Direct Enrichment of O-GlcNAc Peptides by Affinity
Chromatography
Initially, enrichment of O-GlcNAc peptides was based on
immobilized Ricinus communis agglutinin I (RCA I), a
lectin that binds weakly to oligosaccharides with terminal
galactose residues. Hayes et al. [28] used RCA I to retard
the movement of the GalT-labeled form of O-GlcNAc
peptides during chromatography and thus separated them
from mixtures of unmodified peptides, which reduced the
number of HPLC rounds needed to purify O-GlcNAc
peptides and greatly facilitated O-GlcNAc site-mapping
by Edman degradation. Haynes and Aebersold [23] used
the same method to enrich O-GlcNAcylated peptides from
tryptic digests of bovine α-crystallin before site-mapping,
using a triple quadrupole mass spectrometer. Another plant
lectin, wheat germ agglutinin (WGA), binds directly but
very weakly to terminal GlcNAc residues and more
strongly to sialic acids. Using WGA chromatography,
Vosseller et al. [29] enriched 145 unique O-GlcNAc
peptides from neuron postsynaptic density preparation.
The problems of using lectins for enrichment include low
specificity and weak binding affinity. Thus, it is not
unexpected that peptides bearing “classical” O- or N-linked
glycan will coelute with O-GlcNAc peptides and compli-
cate the subsequent mass spectrometric analysis. For the
same reason, Vosseller et al. [29] had to use a ∼39-ft-long
column to retard the elution of O-GlcNAc peptides during
chromatography. However, by directly interfacing this long
nanobore column into the mass spectrometer, they were
able to map many O-GlcNAc sites in these experiments.
Affinity enrichment of O-GlcNAc peptides based on pan-
specific O-GlcNAc antibodies is yet to be proven generally
useful, but little effort has been focused on this approach.
While the antibodies have higher specificity, they also have
low efficiency due to weak binding affinity.
O-GlcNAc Mapping Based on β-elimination
In spite of many other approaches available to selectively
isolate phosphopeptides, β-elimination-based methods for
mapping phosphorylation sites are still widely used to date.
The well-established β-elimination under alkaline condition
cleaves phospho groups from Ser or Thr residues and
generates dehydroalanine (Ser) or dehydrobutyric acid
(Thr). Michael addition with a nucleophilic reagent is then
used to attach an affinity tag to the peptides, enabling
selective enrichment. The same approach can be applied to
enrich O-GlcNAc peptides because O-GlcNAc can be β-
eliminated with even higher efficiency [1, 11–14], allowing
for very mild conditions. Previously, our laboratory
developed a method called β-elimination followed by
Michael addition with dithiothreitol (BEMAD) to enrich
and site-map O-GlcNAc [30]. With this method, tryptic
peptides are first treated with phosphatases to remove
interfering phosphogroups. After β-elimination, dithiothreitol
(DTT) is used as the Michael addition donor. The attached
DTT serves as a tag to enable selective enrichment by thiol-
sepharose resins. This chemical derivatization is also stable
in the mass spectrometer, allowing facile site-mapping by
LC-MS/MS.
Fig. 2 O-GlcNAc peptide ionization is suppressed in presence
of unmodified peptides. A GlcNAcylated peptide YSPTgSPSK
([M+GlcNAc+H]+ 1069.5) and its unmodified form ([M+H]+ 866.4)
are mixed at indicated molar ratios and analyzed by MALDI-TOF
using α-cyano-4-hydroxycinnamic acid as the matrix. Arrows point to
peaks of m/z 1069.5. B GlcNAcylated peptides coelute with their
unmodified forms on reverse-phase HPLC. RF column is packed with
a 10-cm-length of C18 beads. Gradient is 5–40% solvent B (solvent
A: 0.1% formic acid; solvent B: 90% acetonitrile, 0.1% formic acid) in
60 min at a flow rate of 300 nl/min. Extracted ion chromatograms are
shown. Time of elution peaks is as indicated. C GlcNAcylated peptide
YSPTgSPSK ([M+GlcNAc+H]+ 1069.5) is mixed with its unmodified
form ([M+H]+ 866.4) at indicated molar ratios and sprayed into LCQ
mass spectrometer via electrospray ionization. Averaged full scan
spectra are shown. Arrows point to peaks of m/z 1069.5. Peaks of m/z
904.5, 918.3, and 942.5 are due to peptide impurities
b
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McLachlin and Chait [31] reported nonspecific β-
elimination of free hydroxyl groups from Ser or Thr side
chains with extended treatment of base. Li et al. [32]
showed that this side reaction was not detected under mild
alkalinity at ambient temperature for up to 24 h. Thus, these
data suggested that BEMAD experiments should be
performed at room temperature with limited alkalinity.
Barium hydroxide is preferred over sodium hydroxide as the
Fig. 3 Chemoenzymatic approaches for O-GlcNAc peptide enrich-
ment. A Full scan spectra of GlcNAcylated peptide (TAPTgSTIAPG,
[M+GlcNAc+H]+ 1118.5) solution before and after 12-h incubation
with Y289L GalT1 and UDP-azido-Gal. B Flow charts representing
approaches using different functional groups for biotinylation [18, 35,
36]. TCEP, Tris(2-carboxyethyl)phosphine hydrochloride; TBTA, Tris
[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine
10 Clin Proteom (2008) 4:5–13
choice of base since barium provides faster reaction kinetics
without compromising specificity [33]. Since BEMAD is an
indirect method for site mapping, it is essential that a
portion of the sample be used as a negative control that is
pretreated with β-N-acetyl-hexosaminidase to remove all
terminal hexosamines prior to analyses. Another issue of
the current BEMAD method is the suboptimal enrichment
efficiency using thiol-sepharose. A biotinylated reagent was
tried as an alternative for nucleophilic attachment, but it
resulted in other issues, such as low elution efficiency and
reduced MS/MS performance due to fragmentation of the
biotin moiety under CAD condition [30]. Design and
synthesis of new nucleophilic reagents with cleavable
biotin groups may provide a way to improve this technique.
Enrichment Enabled by Chemoenzymatic Labeling
Ramakrishnan and Qasba engineered the β1, 4-galactosyl-
transferase 1 (GalT1) by mutating tyrosine 289 into a
leucine. The single mutation leads to an enlarged donor
substrate-binding pocket and allows the enzyme to tolerate
UDP-GalNAc and its structural analogs [34]. This mutant
enzyme sets the stage for enzymatic labeling of GlcNAc
with UPD-GalNAc analogs that carry a functional group
that can be subsequently conjugated to affinity tag, which
enables specific enrichment. The Y289L GalT1 not only is
able to label full-length GlcNAcylated proteins, but it also
efficiently labels O-GlcNAc peptides. Overnight incubation
of this enzyme with UDP-azido-Gal led to virtually
complete labeling of CTD-GlcNAC peptide (Fig. 3A). This
feature of the enzyme makes this chemoenzymatic ap-
proach not only suitable for isolation and detection of O-
GlcNAcylated proteins, but also ideal for highly efficient
enrichment of O-GlcNAc bearing peptides, which is
critically important for O-GlcNAc site-mapping.
Bülter et al. [35] described a method of synthesizing
UDP-aldo-α-D-galactose (UDP-aldo-Gal) by oxidizing
UDP-Gal with galactose oxidase. Although it has not been
experimentally demonstrated, UDP-aldo-Gal may possibly
be used by GalT1 as the donor substrate to label GlcNAc.
As shown in Fig. 3B, attachment of this functionalized
aldo-Gal to the O-GlcNAc moiety could provide a chemical
handle for subsequent biotinylation reaction with biotin-ɛ-
amidocaproylhydrazide (BACH). After this chemoenzy-
matic tagging, O-GlcNAc peptides could then be easily
isolated from unmodified peptides by avidin chromatography
before mass spectrometric analysis. Khidekel et al. [36]
synthesized UDP-Gal-ketone, which replaced the C-2
N-acetyl moiety with a ketone functional group that could
be biotinylated by conjugating to an aminooxy biotin
derivative after being transferred to O-GlcNAc residues
(Fig. 3B). The authors streamlined this chemoenzymatic
approach and used it to successfully identify dozens of O-
GlcNAcylated proteins from rat brains. Most recently, Wang
et al. [18] used UDP-azido-Gal to directly label O-GlcNAc
peptides by GalT1. The biotinylation was achieved through a
highly selective cycloaddition reaction of alkyne to azide, or
the so-called “Click” chemistry (Fig. 3B). This copper (I)-
catalyzed Click reaction occurs rapidly under very mild
conditions with virtually no side reaction [37]. This is in
contrast to the aldo-BACH and ketone-aminooxy biotin
reaction, which either suffer reaction incompleteness [35] or
require 20–24 h incubation [36]. Biotin conjugation via
Click chemistry generally is complete within 1 h at room
temperature, which avoids potential O-GlcNAc loss during
extended incubation.
For the chemoenzymatic approach, O-GlcNAc peptides
enriched by avidin chromatography will carry an uncharged
bulky tag, which includes a GlcNAc residue, a galactose
residue, a linker arm, and a biotin moiety. The total mass of
this tag on Ser/Thr side chain usually exceeds 700 Da. Data
from our laboratory showed that these tagged peptides
suffered even lower ionization efficiency than peptides
carrying only O-GlcNAc. Also, the O-linkage remains very
labile. Under tandem MS using CAD, the majority of these
peptides will lose the biotin-Gal moiety, while the rest will
just lose the entire tag. Neither case will result in sufficient
peptide backbone fragmentation before O-GlcNAc site
information is lost. To address this issue, Khidekel et al.
[38] combined the recently developed electron-transfer
dissociation (ETD), a mild fragmentation technique that
preserves the O-linkage, with the chemoenzymatic enrich-
ment approach, and unambiguously mapped a number of
O-GlcNAc sites. Alternatively, Wang et al. [18] performed
BEMAD on the enriched peptides, which replaced the
labile GlcNAc-Gal-Biotin tag with a stable nucleophilic
reagent. This simple additional treatment improved ioniza-
tion efficiency and permitted relatively easy O-GlcNAc
site-mapping on intermediate filament protein vimentin
using a conventional CAD tandem mass spectrometer.
New Mass Spectrometric Techniques for O-GlcNAc
Site-mapping
In contrast to the widely used low-energy CAD, which
preferentially breaks O-linkage before fragmenting peptide
backbone, electron capture dissociation (ECD) in the
magnetic field of a Fourier transform ion cyclotron reso-
nance mass spectrometer (FT-ICR-MS) usually preserve
posttranslational modifications on amino acid side chains,
including phosphorylation, glycosylation, and sulfonation
[39]. ETD enables the ECD-type of fragmentation in the
widely used, lower-cost RF quadrupole ion trap mass
spectrometers [40]. ETD has been successfully used in
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studies of phosphoproteomes. However, as a fragmentation
technique only, ETD does not circumvent the necessity of
enriching phosphopeptides. Similarly, ETD alone is not the
ultimate solution for the O-GlcNAc site-mapping problem.
Because O-GlcNAc peptides are substoichiometric and
suffer from severe ion suppression effect, enrichment of
O-GlcNAc peptides is still required before site-mapping by
mass spectrometry.
A potential alternative to circumvent enrichment is to
apply top-down proteomics [41]. Intact proteins or briefly
digested long peptides are highly charged. Thus, the
negative effect of a single O-GlcNAc moiety on ionization
efficiency may be alleviated. Schroeder et al. [42] manually
analyzed the ETD spectra of an abundant peptide that the
search engine failed to assign a sequence to. Based on its
fragmentation pattern together with high mass accuracy and
partial de nova sequencing conferred by FT-MS, they
identified Ser74 as O-GlcNAcylated from a 55-amino-acid
peptide with a charge state of +8. The current database
search engines lack the matching power to assign sequence
or modification status to highly charged peptides based on
their complex MS/MS spectra, which feature also highly
charged fragmentation ions. Hence, manual inspection and
analysis (together with a certain amount of prior knowledge
of the target protein) is usually required. Because of this,
the effectiveness of the top-down proteomic approach for
site-mapping has only been demonstrated on pure, recom-
binant proteins. Applying the same approach to substoi-
chiometric proteins in complex biological mixtures is
challenging.
Site-specific O-GlcNAc Dynamics
Rapid and dynamic regulation of O-GlcNAcylation is
essential in many signaling events. Accumulating evidences
suggest that O-GlcNAc is a nutrient/stress sensor that
modulates many biological functions, including transcrip-
tion regulation, stress response, cell cycle regulation, and
protein turnover [3]. Needless to say, investigating site-
specific O-GlcNAc dynamics will greatly help us to
understand the roles of GlcNAcylation. Fortunately, the
current chemoenzymatic approach for O-GlcNAc peptide
enrichment and site-mapping can be easily combined with
isotopic labeling for quantitative analysis of site-specific O-
GlcNAcylation by mass spectrometry. For example,
Khidekel et al. [38] differentially labeled N-terminal amines
and ɛ-amino groups of lysine residues of the enriched O-
GlcNAc peptides with either hydrogen or deuterium. We
have used natural or deuterated DTT for BEMAD derivati-
zation after O-GlcNAc peptides are enriched from different
biological states. Since dysregulated O-GlcNAcylation is
closely related to diseases like cancer, neurodegenerative
disease, and diabetes [3, 43], quantitative proteomic
analysis of O-GlcNAc dynamics therefore holds great
potential for the discovery of disease mechanisms and
biomarkers.
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